Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

Study Description

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed non-Hodgkin lymphoma. The study will also investigate the safety, toxicity and efficacy of Betalutin and pre-dosing.

Condition or disease	Intervention/treatment	Phase
Non-Hodgkin Lymphoma	Drug: Betalutin with lilotomab dose 1; Drug: Betalutin with lilotomab dose 2	Phase 1

Study Design

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	8 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase 1, Open Label, Randomized Study to Assess Pharmacokinetics, Biodistribution and Radiation Dosimetry of Lutetium (177Lu) Lilotomab Satetraxetan (Betalutin®) Radioimmunotherapy in Patients With Relapsed Non-Hodgkin Lymphoma
Actual Study Start Date :	December 19, 2017
Estimated Primary Completion Date :	September 2019
Estimated Study Completion Date :	September 2020

Arms and Interventions

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Arm 1: Betalutin with lilotomab dose 1; Betalutin 15 MBq/kg b.w. with lilotomab pre-dosing	Drug: Betalutin with lilotomab dose 1; 15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1; Other Names: Betalutin; Lymrit 37-02; lutetium (177Lu) lilotomab satetraxetan; HH1; 177Lu-DOTA-HH1
Experimental: Arm 2: Betalutin with lilotomab dose 2; Betalutin 15MBq/kg b.w. with lilotomab pre-dosing	Drug: Betalutin with lilotomab dose 2; 15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2; Other Names: Betalutin; Lymrit 37-02; lutetium (177Lu) lilotomab satetraxetan; HH1; 177Lu-DOTA-HH1

Outcome Measures

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Dosimetry [ Time Frame: 3 weeks ]
   Estimation of individual tumour/organ uptake and retention of radioactivity.

Secondary Outcome Measures :

1. The number of participants with adverse events as assessed by NCTCAE. [ Time Frame: 12 weeks ]
   Adverse events by treatment group.
2. Efficacy (Best overall response rate) [ Time Frame: 3 months - 1 year ]
   Best overall response rate by treatment group as measured by Cheson Criteria.
3. Lilotomab pharmacokinetics [ Time Frame: 3 weeks ]
   Estimation using decay correction measurements

Eligibility Criteria

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1. Histologically confirmed (by WHO classification) relapsed indolent non-Hodgkin B-cell lymphoma of following subtypes: Follicular lymphoma (follicular grade I-IIIA), Marginal zone lymphoma (exclusion of MZL if large lymphocytes > 50%), Small lymphocytic lymphoma, Lymphoplasmacytoid and classical mantle cell lymphoma (no blastoid MCL).
2. Requiring initiation of treatment for the NHL.
3. Relapsed after at least one line of therapy including rituximab combination chemotherapy regimen.
4. Exhausted and/or ineligible for all standard treatment options.
5. Not a candidate for an autologous or allogeneic stem cell transplantation. Patients in progression after successful stem cell collection before before high-dose therapy and autologous stem cell transplantation may be considered for enrolment.
6. Age ≥ 18 years..
7. A pre-study ECOG performance status of 0-2. In selected patients an ECOG score of 3 can be acceptable if it is clearly lymphoma-associated at the discretion of the investigator.
8. Life expectancy should be ≥ 3 months.
9. 9. < 25% tumour cells in bone marrow biopsy prior to lilotomab/Betalutin treatment (biopsy taken from a site not previously irradiated).
10. All patients must have at least one bi-dimensionally measurable lesion (>1.5 cm in its largest dimension by CT scan). Patients without such a target lesion can be accepted on an individual basis if histological organ involvement can be evaluated for response e.g. involvement of the skin or the gastrointestinal tract.

11. Women of childbearing potential must:

    • have a negative serum pregnancy test at screening and before Betalutin injection
    • understand that the study medication is expected to have teratogenic risk
    • agree to use, and be able to comply with, highly effective method of birth control with a Pearl-Index ≤ 1%. Contraception is required without interruption, 4 weeks before starting study drug, throughout study drug therapy and for 12 months after end of study drug therapy, even if she has amenorrhoea.
12. Male subjects must agree to use condoms during intercourse throughout study drug therapy and the following 12 months.
13. Patients previously treated with native rituximab are eligible.
14. The patient is willing and able to comply with the protocol, and agrees to return to the hospital for follow-up visits and examination.
15. The patient has been fully informed about the study and has signed the informed consent form.
16. Negative HAMA test.
17. CD37 positive, re-biopsy or test on existing tumour material if not known

Exclusion Criteria:

1. Medical contraindications, including uncontrolled infection, severe cardiac, pulmonary, neurologic, psychiatric or metabolic disease, steroid requiring asthma/allergy, known HIV positive.

2. Laboratory values during screening :

   • Absolute Neutrophil Counts (ANC) ≤ 1.5 x 109 /l
   • Platelet count ≤ 150 x 109 /l
   • Total bilirubin ≥ 30 mmol/l
   • ALP and ALAT ≥ 4x normal level
   • GFR < 60 ml/min/1.73 m2 as measured by the CKD-EPI method.
3. Known or suspected CNS involvement of lymphoma
4. Previous total body irradiation, or irradiation of > 25% of the patient's bone marrow.
5. Chemotherapy, immunotherapy or another investigational drug received within the last 4 weeks prior to the patient entering screening.
6. Earlier treatment with radioimmunotherapy.
7. Exposure to another CD37 targeting drug.
8. Concurrent participation in another therapeutic treatment trial.
9. Previous hematopoietic stem cell transplantation (autologous and allogenic).
10. Pregnant or lactating women.
11. Transformed or potentially transformed NHL from indolent to aggressive
12. Receipt of live, attenuated vaccine within 30 days prior to enrolment
13. Test positive for hepatitis B (HBsAg and anti-HBc)
14. A known hypersensitivity to rituximab, HH1, Betalutin or murine proteins or any excipient used in rituximab, HH1 or Betalutin
15. Malignant disease, other than that being treated in this study. Exceptions include: malignancies that were treated curatively and have not recurred within 3 years prior to study entry; completely resected basal cell and squamous cell skin cancers; completely resected carcinoma in situ of any type.

Contacts and Locations

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Contacts

Contact: Clinical Trials	+47 22 18 33 01	clinicaltrials@nordicnanovector.com

Locations

Germany
Universitätsklinikum Würzburg	Recruiting
Würzburg, Germany

Sponsors and Collaborators

Nordic Nanovector

Investigators

Principal Investigator:	Andreas Buck, Prof. MD	Wuerzburg University Hospital

More Information

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications:

Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res. 2013 Jan;33(1):85-95.

Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013 Mar;6(1):20-7.

Responsible Party:	Nordic Nanovector
ClinicalTrials.gov Identifier:	NCT02657447 History of Changes
Other Study ID Numbers:	EudraCT: 2013-003908-39
First Posted:	January 15, 2016
Last Update Posted:	May 3, 2018
Last Verified:	May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Studies a U.S. FDA-regulated Drug Product:		No
Studies a U.S. FDA-regulated Device Product:		No

Keywords provided by Nordic Nanovector:

Betalutin; Radioimmunotherapy; Lu-177; Phase I study; ARC; Antibody Radionuclide Conjugate; HH1; Rituximab; 177Lu-DOTA-HH1; Lymphoma; Lymphoma Non-Hodgkin; Immune System Diseases	Follicular Lymphoma; Marginal Zone Lymphoma; Lymphoplasmacytoid; Lymphatic Diseases; Lymphoproliferative Disorders; Neoplasms; Neoplasms by Histological Type; Small Lymphocytic Lymphoma; Classical Mantle Cell Lymphoma; Lilotomab; Lutetium (177Lu) lilotomab satetraxetan

Additional relevant MeSH terms:

Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms by Histologic Type; Neoplasms	Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases